MX2019012017A - Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. - Google Patents

Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Info

Publication number
MX2019012017A
MX2019012017A MX2019012017A MX2019012017A MX2019012017A MX 2019012017 A MX2019012017 A MX 2019012017A MX 2019012017 A MX2019012017 A MX 2019012017A MX 2019012017 A MX2019012017 A MX 2019012017A MX 2019012017 A MX2019012017 A MX 2019012017A
Authority
MX
Mexico
Prior art keywords
psma
modified form
cells
specific membrane
engineered cells
Prior art date
Application number
MX2019012017A
Other languages
English (en)
Inventor
I Levitsky Hyam
G Pomper Martin
Jeffrey Huss David
MINN Il
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2019012017A publication Critical patent/MX2019012017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computerised tomographs
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se proporcionan células, tales como células modificadas genéticamente, que expresan un antígeno de membrana específico de próstata (PSMA) o una forma modificada del mismo. En algunas modalidades, la célula contiene además un receptor recombinante genéticamente modificado, tal como un receptor de antígeno quimérico, que se une específicamente a un antígeno. La presente descripción también proporciona métodos para detectar, identificar, seleccionar o dirigirse a células que expresan PSMA, tal como en relación con la administración de tales células a sujetos, incluyendo métodos de terapia celular adoptiva, o en relación con métodos de fabricación de células modificadas.
MX2019012017A 2017-04-07 2018-04-07 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. MX2019012017A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762483313P 2017-04-07 2017-04-07
US201762552354P 2017-08-30 2017-08-30
US201762555635P 2017-09-07 2017-09-07
US201762582913P 2017-11-07 2017-11-07
US201862619724P 2018-01-19 2018-01-19
PCT/US2018/026619 WO2018187791A1 (en) 2017-04-07 2018-04-07 Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods

Publications (1)

Publication Number Publication Date
MX2019012017A true MX2019012017A (es) 2020-02-12

Family

ID=62152629

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012017A MX2019012017A (es) 2017-04-07 2018-04-07 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
MX2023005612A MX2023005612A (es) 2017-04-07 2019-10-04 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005612A MX2023005612A (es) 2017-04-07 2019-10-04 Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.

Country Status (8)

Country Link
US (1) US20230190796A1 (es)
EP (1) EP3607319A1 (es)
JP (1) JP7284707B2 (es)
CN (1) CN110730908A (es)
AU (1) AU2018250336A1 (es)
CA (1) CA3056261A1 (es)
MX (2) MX2019012017A (es)
WO (1) WO2018187791A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
US20220411530A1 (en) * 2019-11-22 2022-12-29 Nantong Yichen Biopharma. Co. Ltd. PSMA Antibody and Use Thereof
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US20230098279A1 (en) * 2020-02-18 2023-03-30 Endocyte, Inc. Method of treating psma-expressing cancers
CN112197879B (zh) * 2020-09-14 2021-10-12 中国科学院西安光学精密机械研究所 一种高时间分辨单光子探测方法及单光子探测系统
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4320224A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
JP2024513454A (ja) 2021-04-07 2024-03-25 センチュリー セラピューティクス，インコーポレイテッド キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用
AU2022252997A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
ID28040A (id) 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
DE60107022T2 (de) 2000-07-24 2005-11-24 Health Research Inc. Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030007974A1 (en) 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
ES2528384T3 (es) 2001-12-12 2015-02-09 The Government Of The United States Of America, As Represented By The Secretary Department Of Healt Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20050202020A1 (en) 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
WO2006078892A2 (en) 2005-01-21 2006-07-27 The Regents Of The University Of California Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
US8882573B2 (en) 2005-03-31 2014-11-11 T.C. Airtech, Inc. Ceiling air deflector insert and method of assembly
WO2006110745A2 (en) 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-psma antibodies
AU2006262231B2 (en) 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
JP2009500346A (ja) 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
US20090311225A1 (en) 2005-11-14 2009-12-17 Psma Development Company, Llc Compositions of and Methods of Using Stabilized PSMA Dimers
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
CA2678180A1 (en) 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
AU2008233051B2 (en) 2007-03-30 2014-04-10 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8229090B2 (en) 2007-04-17 2012-07-24 Verizon Patent And Licensing Inc. Voice portal communications
AU2015203742B2 (en) 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
EP2921482B1 (en) 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
HUE059436T2 (hu) 2008-08-01 2022-11-28 Univ Johns Hopkins PSMA-kötõ szerek és alkalmazásaik
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
WO2010135431A2 (en) 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
AU2010249719A1 (en) 2009-05-19 2012-05-31 Aic Blab Company Composite current collector and methods therefor
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
SI2496698T1 (sl) * 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20120067162A1 (en) 2010-09-17 2012-03-22 Steven Kollmann Steering Wheel Armature Weight
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
AU2011343887B2 (en) 2010-12-14 2016-06-16 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
US20140060461A1 (en) 2011-03-31 2014-03-06 General Electric Company Power generation system utilizing a fuel cell integrated with a combustion engine
PE20141271A1 (es) 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
SG194510A1 (en) * 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
WO2013109759A1 (en) 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
US9207122B2 (en) 2012-02-03 2015-12-08 Wayne State University Fourier-transform interferometer with staircase reflective element
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP3064945A1 (en) 2012-02-24 2016-09-07 Cornell University Elevated psma identifies lethal prostate cancers background
WO2013130177A1 (en) 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US9267117B2 (en) 2012-03-15 2016-02-23 New England Biolabs, Inc. Mapping cytosine modifications
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
DE102012009836A1 (de) 2012-05-16 2013-11-21 Carl Zeiss Microscopy Gmbh Lichtmikroskop und Verfahren zur Bildaufnahme mit einem Lichtmikroskop
US9766244B2 (en) 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
AU2013305838A1 (en) 2012-08-20 2015-02-26 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CA2887047A1 (en) 2012-10-05 2014-04-10 Cornell University Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
WO2014205169A1 (en) 2013-06-20 2014-12-24 Exxonmobil Research And Engineering Company Sequential slurry hydroconversion of heavy oils
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
SG11201605605SA (en) 2014-01-10 2016-08-30 Synthon Biopharmaceuticals Bv Method for purifying cys-linked antibody-drug conjugates
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
US10743909B2 (en) 2014-04-03 2020-08-18 Corbin Clinical Resources, Llc Transperineal prostate biopsy device, systems, and methods of use
CA2984484C (en) 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
HUE056023T2 (hu) 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
MA40253A (fr) * 2014-07-15 2017-05-24 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
MA41046A (fr) 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
CA2976360A1 (en) 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US10100126B2 (en) 2015-03-10 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind PSMA
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3522718B1 (en) * 2016-09-02 2023-07-05 Cornell University I domain chimeric antigen receptor specific to icam-1

Also Published As

Publication number Publication date
US20230190796A1 (en) 2023-06-22
MX2023005612A (es) 2023-05-29
WO2018187791A1 (en) 2018-10-11
EP3607319A1 (en) 2020-02-12
CN110730908A (zh) 2020-01-24
JP7284707B2 (ja) 2023-05-31
CA3056261A1 (en) 2018-10-11
JP2020516248A (ja) 2020-06-11
AU2018250336A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
EP3656387A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
NZ765695A (en) Immune cell organoid co-cultures
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
NZ719840A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
MX2022015399A (es) Conjugados de superficie celular y composiciones y metodos celulares relacionados.
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2018001568A (es) Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
WO2018102787A9 (en) Methods for determining car-t cells dosing
MX2019006285A (es) Metodos para modulacion de celulas cart-t.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2021001771A (es) Polipéptidos del receptor de antígeno quimérico en combinación con moléculas del metabolismo trans que modulan el ciclo de krebs y usos terapéuticos de los mismos.
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2020011199A (es) Instrumentacion automatizada para la produccion de bibliotecas de peptidos de receptores de celulas t.
TR201901466T4 (tr) Opti̇mi̇ze edi̇lmi̇ş feli̇n lösemi̇ vi̇rüsü zarf geni̇ni̇ i̇çeren rekombi̇nant feli̇n lösemi̇ vi̇rüsü